Farmers & Merchants Investments Inc. Sells 1,720 Shares of Novartis AG (NYSE:NVS)

Farmers & Merchants Investments Inc. reduced its position in shares of Novartis AG (NYSE:NVSFree Report) by 3.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 45,689 shares of the company’s stock after selling 1,720 shares during the quarter. Farmers & Merchants Investments Inc.’s holdings in Novartis were worth $4,613,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Independence Bank of Kentucky increased its stake in Novartis by 708.5% during the 4th quarter. Independence Bank of Kentucky now owns 1,617 shares of the company’s stock valued at $163,000 after purchasing an additional 1,417 shares in the last quarter. Trust Co. of Oklahoma boosted its holdings in shares of Novartis by 4.5% in the fourth quarter. Trust Co. of Oklahoma now owns 12,098 shares of the company’s stock worth $1,222,000 after buying an additional 518 shares during the last quarter. Pinnacle Financial Partners Inc boosted its holdings in shares of Novartis by 14.7% in the fourth quarter. Pinnacle Financial Partners Inc now owns 5,263 shares of the company’s stock worth $531,000 after buying an additional 676 shares during the last quarter. Prio Wealth Limited Partnership boosted its holdings in shares of Novartis by 4.6% in the fourth quarter. Prio Wealth Limited Partnership now owns 2,503 shares of the company’s stock worth $253,000 after buying an additional 110 shares during the last quarter. Finally, Ascent Wealth Partners LLC boosted its holdings in shares of Novartis by 1.0% in the fourth quarter. Ascent Wealth Partners LLC now owns 15,971 shares of the company’s stock worth $1,613,000 after buying an additional 157 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Novartis in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $114.00 price objective on the stock. BMO Capital Markets started coverage on shares of Novartis in a report on Friday, February 23rd. They issued a “market perform” rating and a $114.00 price objective on the stock. HSBC downgraded shares of Novartis from a “buy” rating to a “hold” rating in a report on Monday, December 18th. Finally, StockNews.com started coverage on shares of Novartis in a report on Wednesday, December 6th. They set a “strong-buy” rating on the stock. Three research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.33.

Check Out Our Latest Analysis on Novartis

Novartis Price Performance

Shares of NYSE:NVS opened at $94.41 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.15 and a quick ratio of 0.93. Novartis AG has a 1-year low of $92.09 and a 1-year high of $108.78. The company has a market capitalization of $200.11 billion, a P/E ratio of 13.15, a P/E/G ratio of 1.49 and a beta of 0.54. The firm’s 50 day simple moving average is $101.05 and its two-hundred day simple moving average is $99.68.

Novartis (NYSE:NVSGet Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $11.42 billion for the quarter, compared to analysts’ expectations of $11.69 billion. Novartis had a net margin of 29.83% and a return on equity of 29.90%. During the same period in the prior year, the firm earned $1.51 EPS. Research analysts expect that Novartis AG will post 7.17 EPS for the current fiscal year.

Novartis Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, March 7th. Stockholders of record on Friday, March 8th were given a dividend of $3.7772 per share. The ex-dividend date of this dividend was Thursday, March 7th. This represents a dividend yield of 3.1%. This is a boost from Novartis’s previous annual dividend of $3.47. Novartis’s dividend payout ratio (DPR) is presently 34.26%.

Novartis Company Profile

(Free Report)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Featured Stories

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVSFree Report).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.